- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-DD: MorphoSys AG: Dr. Marc Cluzel, buy
- EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
- EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
- EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
- EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
- EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
- EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
- EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
- EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
MorphoSys AG (0NDV:LSE) closed at 14.61, 4.88% above its 52-week low of 13.93, set on Nov 16, 2022.
13.93Nov 16 202238.04Nov 25 2021
Markit short selling activity
|Market cap||506.98m EUR|
|EPS (TTM)||-25.23 |
Data delayed at least 20 minutes, as of Nov 25 2022 17:58 GMT.